tetano
Editor, Senior Moderator
J Korean Med Sci
. 2024 Sep 30;39(37):e258.
doi: 10.3346/jkms.2024.39.e258. Effectiveness of the Bivalent mRNA COVID-19 Vaccine for Preventing Critical Infection From the SARS-CoV-2 Omicron Variant in the Republic of Korea
Young-Sook Choi[SUP] #[/SUP][SUP] 1 [/SUP], Sukhyun Ryu[SUP] #[/SUP][SUP] 2 [/SUP], Ryu Kyung Kim[SUP] 3 [/SUP], Achangwa Chiara[SUP] 2 [/SUP], Soojin Baek[SUP] 1 [/SUP], Hojin Nam[SUP] 1 [/SUP], Eunkyung Park[SUP] 1 [/SUP], Eun Kyoung Kim[SUP] 1 [/SUP], Young June Choe[SUP] 4 [/SUP], Donghyok Kwon[SUP] 5 [/SUP], Won Suk Choi[SUP] 6 [/SUP]
Affiliations
Background: This retrospective observational matched cohort study assessed the differences in critical infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the omicron-predominant period of the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the vaccine effectiveness of bivalent mRNA vaccine compared to unvaccinated individuals.
Methods: We collected COVID-19 case data from the Korean COVID-19 vaccine effectiveness cohort. We calculated the probability of critical COVID-19 cases by comparing the vaccinated and unvaccinated groups.
Results: The risk of being critically infected due to SAR-CoV-2 infection was 5.96 times higher (95% confidence interval, 5.63-6.38) among older individuals who were unvaccinated compared to those who received the bivalent COVID-19 vaccine.
Conclusion: Our findings indicate that the bivalent vaccine reduces the disease burden of the SARS-CoV-2 omicron variant, particularly among the older population. Further studies are warranted to determine the effectiveness of booster doses of vaccines for SARS-CoV-2 infection.
Keywords: COVID-19; Older People; SARS-CoV-2; Vaccine Effectiveness; Vaccine, Bivalent.
. 2024 Sep 30;39(37):e258.
doi: 10.3346/jkms.2024.39.e258. Effectiveness of the Bivalent mRNA COVID-19 Vaccine for Preventing Critical Infection From the SARS-CoV-2 Omicron Variant in the Republic of Korea
Young-Sook Choi[SUP] #[/SUP][SUP] 1 [/SUP], Sukhyun Ryu[SUP] #[/SUP][SUP] 2 [/SUP], Ryu Kyung Kim[SUP] 3 [/SUP], Achangwa Chiara[SUP] 2 [/SUP], Soojin Baek[SUP] 1 [/SUP], Hojin Nam[SUP] 1 [/SUP], Eunkyung Park[SUP] 1 [/SUP], Eun Kyoung Kim[SUP] 1 [/SUP], Young June Choe[SUP] 4 [/SUP], Donghyok Kwon[SUP] 5 [/SUP], Won Suk Choi[SUP] 6 [/SUP]
Affiliations
- PMID: 39355951
- PMCID: PMC11444818
- DOI: 10.3346/jkms.2024.39.e258
Background: This retrospective observational matched cohort study assessed the differences in critical infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the omicron-predominant period of the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the vaccine effectiveness of bivalent mRNA vaccine compared to unvaccinated individuals.
Methods: We collected COVID-19 case data from the Korean COVID-19 vaccine effectiveness cohort. We calculated the probability of critical COVID-19 cases by comparing the vaccinated and unvaccinated groups.
Results: The risk of being critically infected due to SAR-CoV-2 infection was 5.96 times higher (95% confidence interval, 5.63-6.38) among older individuals who were unvaccinated compared to those who received the bivalent COVID-19 vaccine.
Conclusion: Our findings indicate that the bivalent vaccine reduces the disease burden of the SARS-CoV-2 omicron variant, particularly among the older population. Further studies are warranted to determine the effectiveness of booster doses of vaccines for SARS-CoV-2 infection.
Keywords: COVID-19; Older People; SARS-CoV-2; Vaccine Effectiveness; Vaccine, Bivalent.